...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases
【24h】

Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases

机译：化疗加上贝伐单抗作为结直肠肝转移患者的新辅助或转化处理

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: To evaluate the efficacy of chemotherapy plus bevacizumab as neoadjuvant or conversion treatment for colorectal liver metastases (CLM). Patients and Methods: A retrospective chart review was carried out of 74 patients with CLM treated with neoadjuvant or conversion chemotherapy plus bevacizumab. Results: The overall response rate was 63.4%. An optimal morphological response by computed tomography was reported in 35% of patients. The rate of complete resection was 71.6%. Complete or major pathological response (pR) was attained in 58.2%. The median overall survival (OS) was not reached. Median progression free (PFS) and relapse free (RFS) survival were 14.6 and 8.7 months. Among patients reaching an optimal pR, median OS was not reached (p=0.08), and a trend towards longer RFS and PFS was seen. Conclusion: Neoadjuvant or conversion chemotherapy with bevacizumab is an active and tolerable option for CLM with minimal postsurgery complications. Optimal pR is associated with a longer OS and a trend for prolonged PFS and RFS.
机译：目的：评估化疗加贝伐单抗作为结直肠肝转移（CLM）的新辅助或转化处理的疗效。患者和方法：回顾性图表审查中的74例CLM患者进行了Neoadjuvant或转化化疗加上Bevacizumab。结果：整体反应率为63.4％。在35％的患者中报告了计算断层扫描的最佳形态反应。完全切除率为71.6％。完成或重大病理反应（PR）以58.2％达到。未达到中位数生存（OS）。中位进展免费（PFS）和复发免费（RFS）生存率为14.6和8.7个月。在达到最佳PR的患者中，未达到中值操作系统（P = 0.08），并且看到了更长的RFS和PFS的趋势。结论：Neoadjuvant或转化化疗与BeVacizumab是CLM的活性和可耐受的选择，后期并发症最小。最佳PR与较长的操作系统相关联，延长PFS和RFS的趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号